Unitak

Unitak (Suzhou) Biopharmaceutical is a China-based biotechnology company dedicated to the discovery and development of next-generation antibody-drug conjugates (ADCs) for oncology. Founded in 2020 and headquartered in the Suzhou BioBAY, the company utilizes a proprietary ADC platform that emphasizes site-specific conjugation and innovative linker-payload combinations to enhance therapeutic efficacy and safety. Its lead candidate, UTK-001, is a HER2-targeted ADC designed to treat various HER2-expressing solid tumors, including breast and gastric cancers. Unitak's pipeline also includes programs targeting Trop2 and other validated oncology markers, aiming to provide superior treatment options for patients with refractory or resistant cancers.